Literature DB >> 19508654

Higher skeletal muscular metabolic reserve capacity in COPD patients than healthy subjects.

B Rud1, C C Christensen, M Ryg, A Edvardsen, S Skumlien, J Hallén.   

Abstract

We investigated the interaction between skeletal muscle exercise capacity and central restrictions using exercise modalities, which recruit differing levels of muscle mass in eight patients chronic obstructive lung disease (COPD) (FEV(1)% of predicted; 35 [SE 4%]) and eight healthy controls. Subjects performed conventional bicycling, two-leg knee extensor (2-KE) and single-leg knee extensor (1-KE) exercises. Maximal values for pulmonary VO(2) (VO(2max)), power output, blood lactate, heart rate, blood pressure, and arterial oxygen saturation of hemoglobin were registered. VO(2max) in controls was 2453 (210), 1468 (124), and 976 (76) mL/min during bicycling, 2-KE and 1-KE, respectively. The COPD patients achieved 48% (P<0.05), 62% (P<0.05), and 81% (P=0.10) of the control values. The mass-specific VO(2max) (VO(2max)/exercising muscle mass) during 1-KE was 345 (25) and 263 (30) mL/kg/min (P<0.05) in controls and COPD patients, respectively. During 2-KE the controls and COPD patients achieved 85% (4%) and 67% (5%) (P=0.06) of the mass-specific VO(2) during 1-KE, while during bicycling they achieved 31% (2%) and 17% (1%) (P<0.05), respectively. The COPD patients have central restrictions when exercising with a relatively small muscle mass (2-KE) and have a higher muscular metabolic reserve capacity than controls during whole body exercise.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19508654     DOI: 10.1111/j.1600-0838.2008.00846.x

Source DB:  PubMed          Journal:  Scand J Med Sci Sports        ISSN: 0905-7188            Impact factor:   4.221


  1 in total

1.  Is the balance between skeletal muscular metabolic capacity and oxygen supply capacity the same in endurance trained and untrained subjects?

Authors:  Bjarne Rud; Jostein Hallén
Journal:  Eur J Appl Physiol       Date:  2008-12-02       Impact factor: 3.078

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.